因子XI抑制对肿瘤细胞诱导的凝血激活的影响
本研究通过单阶段凝血试验和凝血酶生成试验,分析4种表达组织因子(TF)的肿瘤细胞系在FXIa抑制剂BMS-262084、抑制性FXI抗体、利伐沙班或亭扎肝素峰值及谷值浓度下的促凝活性。结果显示FXI/FXIa抑制仅在低TF促凝活性水平下有效减轻肿瘤细胞诱导的纤维蛋白凝块形成和血小板聚集,抗凝效果与细胞TF促凝活性表达呈负相关。
要点
- FXIa抑制剂BMS-262084和抗FXI抗体仅在低TF促凝活性水平下有效抑制肿瘤细胞诱导的凝血激活。
- FXIa抑制的抗凝效果与肿瘤细胞TF促凝活性表达量呈负相关。
- 利伐沙班和亭扎肝素在高TF促凝活性水平下也表现出显著抗凝活性。
核心结论
- FXI/FXIa抑制仅在低TF促凝活性表达水平下干扰肿瘤细胞诱导的凝血激活,该发现可能对未来体内研究有潜在意义。
研究设计与样本
- 体外研究,分析4种表达组织因子的肿瘤细胞系的促凝活性,采用单阶段凝血试验和凝血酶生成试验,并记录肿瘤细胞诱导的血小板聚集。
主要发现
- BMS和抗FXI抗体在低TF促凝活性存在时有效减轻重组人TF和肿瘤细胞诱导的纤维蛋白凝块形成及血小板聚集。
- 抗凝效果与细胞TF促凝活性表达量呈负相关。
- BMS显著干扰肿瘤细胞诱导的凝血酶生成,对峰值和总凝血酶影响最显著。
- 在低TF促凝活性水平下,10 μM BMS的抗凝效果与600 nM利伐沙班和1.6 μM亭扎肝素相似。
- 利伐沙班和亭扎肝素在高TF促凝活性水平下也表现出显著抗凝活性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer-associated thrombosis is a frequent complication in patients with malignancies. While factor XI (FXI)/FXIa inhibition is efficacious in preventing postoperative venous thromboembolism, its role in tumor cell-induced coagulation is less defined. OBJECTIVES: We thus aimed to provide mechanistic insights into FXI/FXIa inhibition in tumor cell-induced coagulation activation. METHODS: Procoagulant activity (PCA) of 4 different tissue factor (TF) expressing tumor cell lines was analyzed by single-stage clotting and thrombin generation assay in the presence of a FXIa inhibitor, BMS-262084 (BMS), an inhibitory FXI antibody (anti-FXI), or peak and trough concentrations of rivaroxaban or tinzaparin. Further, tumor cell-induced platelet aggregation was recorded. Recombinant human TF served as positive control. RESULTS: Although BMS and anti-FXI potently inhibited FXIa amidolytic activity, both inhibitors efficiently mitigated recombinant human TF- and tumor cell-induced fibrin clot formation and platelet aggregation only in the presence of low TF PCA. The anticoagulant effects showed an inverse correlation with the magnitude of cellular TF PCA expression. Similarly, BMS markedly interfered with tumor cell-induced thrombin generation, with the most prominent effects on peak and total thrombin. In addition, anticoagulant effects of FXIa inhibition by 10 μM BMS were in a similar range to those obtained by 600 nM rivaroxaban and 1.6 μM tinzaparin at low TF PCA levels. However, rivaroxaban and tinzaparin also exerted marked anticoagulant activity at high TF PCA levels. CONCLUSION: Our findings indicate that FXI/FXIa inhibition interferes with tumor cell-induced coagulation activation only at low TF PCA expression levels, a finding with potential implications for future in vivo studies.
引用
- Mäder J, Rolling CC, Voigtländer M, et al. Effect of factor XI inhibition on tumor cell-induced coagulation activation. J Thromb Haemost. 2023. PMID: 37751848. doi:10.1016/j.jtha.2023.09.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。